Cellular macromolecular thiol groups

Cellular macromolecular thiol groups represent a collective chemical target for hypoxia-selective bioreductive drugs and imaging probes. In the low-oxygen environment characteristic of solid tumors, nitroimidazole derivatives such as pimonidazole undergo enzymatic reduction by intracellular reductases to form highly reactive intermediates (Raleigh et al., 1998, PubMed ID: 9671407). These reactive species then form stable covalent adducts with the sulfhydryl (-SH) groups of intracellular proteins and other macromolecules (Arteel et al., 1995, PubMed ID: 7641143). This process is utilized both for therapeutic purposes, to concentrate cytotoxic agents in hypoxic regions, and for diagnostic purposes, where the resulting adducts serve as immunohistochemical markers for tumor hypoxia (Varia et al., 1998, PubMed ID: 9730462). Because these thiols are ubiquitous, the specificity of the interaction is driven by the oxygen-dependent activation of the drug rather than the uniqueness of the thiol group itself. This mechanism is critical for identifying treatment-resistant hypoxic zones in tumors and for the development of hypoxia-activated prodrugs (Varghese et al., 1980, PubMed ID: 7434358).

Other names

Protein thiol groupsCellular sulfhydryl groupsMacromolecular sulfhydrylsProtein-SH groups

Enzymatic bioreduction of nitro groups to reactive intermediates followed by covalent conjugation to sulfhydryl groups on cellular proteins.